Autoimmune Disease Treatment Market Size, Share, Growth, and Industry Analysis, By Type (Immunosuppressant’s, Anti-Inflammatory Drugs, Corticosteroids, Nonsteroidal Anti-inflammatory Drugs, Biologics), By Application (Hospitals, Clinics, Drug Stores, Other), Regional Insights and Forecast to 2031

Updated On: 29 April 2024

AUTOIMMUNE DISEASE TREATMENT MARKET REPORT OVERVIEW

• 

• to learn more about this report

The global autoimmune disease treatment market size was USD 98160 million in 2020 and the market is projected to touch USD 119350 million by 2027, exhibiting a CAGR of 2.4% during the forecast period.

A group of diseases called autoimmune diseases are caused by the immune system attacking the body and healthy cells, causing tissue damage and inflammation. According to the Autoimmune Disease Association of America, about 50 million people have autoimmune diseases, making them the leading cause of morbidity and mortality in the United States.

The two main drivers of the market and growth are the increasing prevalence of autoimmune diseases and the wider understanding of these diseases.

COVID-19 Impact: Market Growth Restrained by Pandemic due to Supply Chain Disruptions

The global COVID-19 pandemic has been unprecedented and staggering, with the market experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to market’s growth and demand returning to pre-pandemic levels.

The pandemic affects the treatment of a multifactorial disease such as rheumatoid arthritis (RA). Patients are at greater risk of infection than the general population due to the general weakening of the immune system associated with autoimmune diseases and the iatrogenic effects of immunosuppressive and corticosteroid drugs. However, increasing awareness of the pathophysiology of severe acute respiratory infection is leading to some antirheumatic drugs being considered as potential options in the treatment and management of COVID-19, leading to growth in the autoimmune disease treatment market.

LATEST TRENDS

"Improvements In Healthcare Infrastructure And Technology Bring With Them Several Opportunities For Growth "

A number of tests are used to diagnose autoimmune diseases, and in some cases, they can help determine the severity of the disease. In addition to identifying the type of disease, the correct autoimmune blood test can point patients to the necessary treatment plans and lifestyles. Public awareness of the diagnosis of these conditions is increasing due to the increasing prevalence of autoimmune diseases. These factors are expected to drive the autoimmune disease treatment market growth during the forecast period. Advances in technology such as new biomarkers such as Humira and Enbrel, creation of compact diagnostic point-of-care devices, and increasing popularity of laboratory robotics are projected to stimulate growth during the forecast period. The sector is increasing due to the ever-improving healthcare infrastructure and rising healthcare costs. The introduction of advanced technology to improve treatment may alert more people to the use of the drug. Market value of autoimmune treatment may increase with higher adoption. Increased government spending on better medical facilities has several potential benefits for market expansion. New competitors may have opportunities in the global market for the treatment of autoimmune diseases due to the increased availability of biosimilars and more affordable treatments.

AUTOIMMUNE DISEASE TREATMENT MARKET SEGMENTATION

• 

• to learn more about this report

• By Type

Based on type the global market can be categorized into Immunosuppressant’s, Anti-Inflammatory Drugs, Corticosteroids, Nonsteroidal Anti-inflammatory Drugs, Biologics.

Immunosuppressants are drugs that prevent or reduce the strength of the body's immune response.

Anti-inflammatory drugs are a class of FDA-approved drugs for use as antipyretics, anti-inflammatory drugs, and pain relievers.

NSAIDs are a class of drugs used to treat pain, fever and other inflammatory processes. This activity describes the indications, mechanism of action, route of administration, side effects, contraindications, monitoring and important points for providers of NSAIDs.

• By Application

Based on application the global market can be categorized into Hospitals, Clinics, Drug Stores, Other.

Hospitals accounted for the largest market share in the segment in 2022 due to rapid adoption of advanced products and skilled nursing workforce. Additionally, government initiatives to improve healthcare infrastructure and seasonal affective disorder surgeries such as minimally invasive spine surgeries and others are expected to increase momentum during the forecast period. 

In contrast, the clinic segment is growing fastest in the post-pandemic period due to various health needs.  The fastest growing and dominant segment in the field of seasonal affective disorder is the household.

A pharmacy (also called a pharmacy or community pharmacy or pharmacist in American English) is a retail store that offers drugs, among other products.

DRIVING FACTORS

"Increasing Prevalence Of Several Autoimmune Diseases Is Driving The Growth Of The Global Market."

Factors driving the global autoimmune disease treatment market and growth include increasing prevalence of autoimmune diseases, increased patient awareness, and increased laboratory automation that enables multiple diagnostic tests to be performed simultaneously, resulting in faster and more accurate findings, thus increasing patient numbers. awareness of such disruptions will drive market expansion. Autoimmune disease targets healthy tissues, cells and organs. It can affect any part of the body, weaken body functions and threaten life. These conditions sometimes require lifelong treatment to control symptoms, as there is no known cure. Autoimmune diseases develop significantly faster in women compared to men. The disease is rated as the 10th leading cause of death in women under the age of 65 and the second leading cause of chronic disease. In addition, it is the most common cause of disease in women in the United States. There are currently more than 80 clinically distinct autoimmune diseases. As a result, the autoimmune disease treatment market will expand during the forecast period.

"Increasing activity of R&D and increasing incidence of autoimmune diseases are driving the growth of the market"

Most important are the increase in the incidence of autoimmune diseases, the explosion in the use of drugs to treat autoimmune diseases, and the expansion of R&D's efforts to provide the best drugs.  Market Leaders in Autoimmune Disease Treatment. In addition, the availability of therapeutic technological advances in screening methods and the availability of drugs in development such as tocilizumab, baricitinib, secukinumab, etanercept, elotuzumab, abatacept, apremilast, golimumab, ustekinumab, certolizumab and tofacitinib market size of autoimmune treatment expected to grow as prevalence of autoimmune diseases increases and when people are more aware of the need to use medicines for them. Market growth is expected to accelerate with the rise of autoimmune diseases. The prevalence of autoimmune diseases is increasing, which worries European countries. According to the Multiple Sclerosis Trust, there will be 2.5 million people with multiple sclerosis in the world in 2020, with the highest incidence in Europe. Multiple sclerosis affects women more often than men. Multiple sclerosis affects women more often than men. Two million people have rheumatoid arthritis, while 2-3% of the population has psoriasis, one of the most common autoimmune diseases. Raising awareness of autoimmune diseases through research, education, support and advocacy initiatives is one of the most important factors influencing the increase in utilization rates.

RESTRAINING FACTORS

"Lack Of Funds And High Costs Associated With Treatment Of Diseases Can Hinder The Growth Of The Global Market."

The main factors restraining the global autoimmune disease treatment market are insufficient funding in developing countries, high cost of treating the disease, availability of drugs in developing countries and development of alternative technologies. Lack of understanding and awareness of autoimmune diseases and their symptoms in poor and remote areas would reduce their use in underdeveloped and lower income countries.

AUTOIMMUNE DISEASE TREATMENT MARKET REGIONAL INSIGHTS

• 

• to learn more about this report

"North America Dominating the Market due to Increasing Availability Of Various Treatment Options"

The market is primarily segmented into Europe, Latin America, Asia Pacific, North America and Middle East and Africa.

North America dominates the autoimmune disease treatment market share due to increasing availability of various treatment options, rising consumer awareness about autoimmune diseases and high patient population in the region. North America is a predicted region for the growth of the autoimmune therapy market due to increasing availability of various treatment options, consumer awareness about autoimmune diseases and large patient population in the region.

KEY INDUSTRY PLAYERS

"Key Industry Players Shaping the Market through Innovation and Market Expansion"

Prominent Autoimmune Disease Testers are adopting various strategies to strengthen their position as market leaders. One such key strategy is to acquire companies to enhance brand value among users. Another important strategy is the periodic launch of innovative products, during which the market and its target group are studied in detail. Their strong global presence and brand recognition have contributed to increased consumer trust and loyalty, driving product adoption. Moreover, these industry giants continually invest in research and development, introducing innovative designs, materials, and smart features, catering to evolving consumer needs and preferences. The collective efforts of these major players significantly impact the competitive landscape and future trajectory of the market.

List of Market Players Profiled

• Abbott Laboratories (U.S.)
• Active Biotech (Sweden)
• Eli Lilly (U.S.)
• Bristol-Myers Squibb (U.S.)
• AstraZeneca plc (U.K.)
• Pfizer (Japan)
• Biogen Idec (U.S.)
• GlaxoSmithKline (U.K.)
• Amgen (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Johnson & Johnson (U.S.)
• Bayer (Germany)

INDUSTRIAL DEVELOPMENT

May 2022: Thermo Fisher Scientific has announced that the Phadia 2500+ device for autoimmune diseases is available in the United States.  testing This device enables autoimmune diagnostics to help diagnose autoimmune diseases, including celiac disease, rheumatoid arthritis, autoimmune liver disease and autoimmune thyroid disease, e.g. This strategic the launch helped the company generate business revenue and improve its customer base.

REPORT COVERAGE

The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.

The research report delves into market segmentation, utilizing both qualitative and quantitative research methods to provide a thorough analysis. It also evaluates the impact of financial and strategic perspectives on the market. Furthermore, the report presents national and regional assessments, considering the dominant forces of supply and demand that influence market growth. The competitive landscape is meticulously detailed, including market shares of significant competitors. The report incorporates novel research methodologies and player strategies tailored for the anticipated timeframe. Overall, it offers valuable and comprehensive insights into the market dynamics in a formal and easily understandable manner.